Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
BD expands its PureWick line with a portable system built for discreet, mobile incontinence care, aiming to deepen its home-care reach.
Becton, Dickinson and Company ( BDX ) Q4 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Adam Reiffe Thomas Polen - President, CEO & Chairman Christopher DelOrefice - Executive VP & CFO Conference Call Participants Travis Steed - BofA Securities, Research Division Patrick Wood - Morgan Stanley, Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Frederick Wise - Stifel, Nicolaus & Company, Incorporated, Research Division Presentation Operator Hello, and welcome to BD's Fourth Quarter and Full Year Fiscal 2025 Earnings Call. At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at (800) 839-2383 for domestic calls and area code +1 402 220-7202 for international calls.
| - Industry | - Sector | Thomas E. Polen Jr. CEO | LSE Exchange | US0758871091 ISIN |
| US Country | 70,000 Employees | 8 Dec 2025 Last Dividend | 1 Apr 2022 Last Split | - IPO Date |
Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.
This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.
In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.
BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.